Study wrapper · #1097
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.
Lechner B, Lechner K, Freibothe I, et al. Cardiovascular diabetology. Endocrinology reports. 2026.
DOI: 10.1186/s40842-026-00318-zPubMed: 42538551
Editor's note
This case report explores tirzepatide's use in a setting where incretin therapy is often withheld, describing a favorable course that the authors explicitly frame as association rather than causation. As a single-patient observation it is hypothesis-generating and should be read in that light.
Plain-language abstract
This single case describes a woman with recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes whose triglycerides normalized and pancreatitis episodes stopped after tirzepatide was started. The authors emphasize this is an association only and does not establish causality.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026